TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis

Lane, Michael A.; McDonald, Jay R.; Zeringue, Angelique; Caplan, Liron; Curtis, Jeffrey R.; Ranganathan, Prabha; Eisen, Seth A.

doi:10.1097/md.0b013e318211106a

Cited by 72 publications

(57 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the other registries and cohort studies, the increased age-related risk is conflicted. An increased risk of infection has been documented in a cohort of veterans and a retrospective cohort of Canadians age Ͼ66 years (18,19). No increased risk of infection with age was reported for the first time by Schneeweiss et al in a population of 15,597 patients age Ͼ75 years initiating anti-TNF therapy, and has also not been seen in the Swiss and Dutch anti-TNF registries (20 -22).…”

Section: Discussionmentioning

confidence: 89%

Efficacy and Safety of Rituximab in Elderly Patients With Rheumatoid Arthritis Enrolled in a French Society of Rheumatology Registry

Payet

Soubrier

Perrodeau³

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. The aim of this study was to compare the efficacy and safety of rituximab (RTX) as a function of patient age. Methods. We included all rheumatoid arthritis patients in the AutoImmunity and Rituximab registry with a 2-year followup. Results. Of the 1,709 patients, 191 were age >75 years, 417 were ages 65-74 years, 907 were ages 50 -64 years, and 194 were age <50 years. At baseline, the elderly and very elderly patients presented with longer disease duration, a higher incidence of erythrocyte sedimentation rate and C-reactive protein level, a lower incidence of previous tumor necrosis factor ␣ (TNF␣) therapy, and a smaller number of previously used TNF␣ agents. Disease activity, rheumatoid factor (RF), or anti-cyclic citrullinated peptide (anti-CCP) antibodies and corticosteroid therapy were not statistically different among the groups. At 24 months, no significant difference was shown among the groups for RTX discontinuation rates (36.1% if age <50 years, 32.6% if ages 50 -64 years, 34.5% if ages 65-74 years, and 32.5% if age >75 years). The reasons for discontinuation (inefficacy, adverse events) were the same in all 4 groups. Infections were more common in the elderly. Patients ages 65-75 years were more likely to be good responders than nonresponders at 1 year of followup than patients age >75 years (odds ratio 3.81, 95% confidence interval 1.14 -12.79) after adjustment on disease duration, RF/anti-CCP positivity, corticosteroids, anti-TNF use, and baseline Disease Activity Score in 28 joints (DAS28). After the sixth month, the decrease in DAS28 score was less marked in the population age >75 years than in the group age <50 years. Conclusion. The efficacy and safety of RTX is affected by age.

show abstract

Section: Discussionmentioning

confidence: 89%

Efficacy and Safety of Rituximab in Elderly Patients With Rheumatoid Arthritis Enrolled in a French Society of Rheumatology Registry

Payet

Soubrier

Perrodeau³

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Lane и соавт. [80] продемонстрировали, что частота СКИ, требу-ющих госпитализации, составила 7%. При этом значимыми факторами риска развития СКИ были лечение преднизоло-ном (ОР 2,14; 95% ДИ 1,88-2,43) или иФНОα (ОР 1,24; 95% ДИ 1,02-1,50).…”

Section: пневмонияunclassified

Targeted Therapy and Infections in Rheumatic Diseases

Белов¹,

Наумцева²,

Тарасова³

et al. 2016

RJTAO

View full text Add to dashboard Cite

Ушедший в историю ХХ век ознаменовался беспреце-дентно активной борьбой с инфекционными заболевания-ми и принес целую серию блестящих открытий и достиже-ний в этой области. Однако в наступившем XXI веке инфек-ционные болезни по-прежнему сохраняют свою значимость как в медицинском, так и в социальном плане. Возрастаю-щее число вновь открываемых инфекционных болезней, возрождение ликвидированных нозологических форм, ус-тановление инфекционной природы ряда заболеваний -все это стало предметом повседневного внимания врачей различных специальностей, в том числе ревматологов.Несомненного внимания в современной ревматологии заслуживает проблема коморбидных инфекций (КИ), фор-мирование которых обусловлено как самим ревматическим заболеванием (РЗ), так и необходимостью применения пре-паратов с иммуносупрессивным действием. КИ оказывают значительное влияние на морбидность и летальность, осо-бенно при диффузных болезнях соединительной ткани. Данная проблема в последние годы стала еще более важной в связи с активным и все нарастающим внедрением в кли-ническую практику генно-инженерных биологических пре-паратов (ГИБП), действие которых направлено на специ-фические компоненты патогенеза РЗ. Применение ГИБП позволило достичь больших успехов, в первую очередь в ле-чении ревматоидного артрита (РА). Сегодня ГИБП включе-ны во все национальные и международные руководства по (TB, pneumonia, chronic viral hepatitis, herpesvirus infection, etc.)

show abstract

“…Ovi nalazi su bili nezavisni od starosti, pola i statusa pušenja. Potrošnja oralnih kortikosteroida se smanjila za 50%, dok je stopa imunizacije oboljelih od RA protiv gripa poboljšana za 86%, a protiv pneumokoka do 65% [24][25][26][27][28][29][30].…”

Section: Diskusijaunclassified

Komorbiditeti kod oboljelih od reumatoidnog artritisa

Radić

Prodanović

Kovačević

et al. 2016

Biomedicinska istraž.

View full text Add to dashboard Cite

Kratak sadržajUvod. Reumatoidni artritis je sistemsko, autoimunsko oboljenje koje dovodi do deformacija i destrukcija zglobova, smanjujući radnu sposobnost oboljelog i značajno utičući na kvalitet života. Bolest u oko 80% bolesnika počinje postepeno, a klinički se ispolji nakon neke infekcije, tjelesne ili psihičke traume, ili porođaja. Komorbiditeti (pridružena oboljenja) nisu rijetki kod bolesnika sa reumatoidnim artritisom, pa prosječno kod pojedinog bolesnika sa reumatoidnim artritisom postoji 1,6 komorbiditeta. Cilj istraživanja je ispitivanje učestalosti pridruženih bolesti kod bolesnika sa reumatoidnim artritisom, kao i promjene te učestalosti tokom jednogodišnjeg praćenja.Metode. Istraživanjem je obuhvaćeno 50 bolesnika sa reumatoidnim artritisom koji su liječeni ambulantno i hospitalno na području Hercegovine. Dijagnoza je postavljena prema revidiranim kriterijumima Američkog udruženja reumatologa iz 1987. godine.Rezultati. Među bolesnicima liječenim od reumatoidnog artritisa bilo je više žena (74%) nego muškaraca (20%). Prosječna starosna dob žena bila je 55,6±12,6 godina, a muškaraca 58,1±11,2 godine. Najveći broj ispitanika (26%) oboljelih od reumatoidnog artritisa imalo je kardiovaskularne bolesti (hipertenzija, angina pektoris, valvularne bolesti srca), 12% ispitanika bolesti endokrinog sistema (diabetes mellitus i bolesti štitaste žlijezde) i 4% ispitanika bolesti gastrointestinalnog trakta. Tokom praćenja povećavala se učestalost svih komorbiditeta.Zaključak. Visok procenat bolesnika sa reumatoidnim artritisom ima pridružena oboljenja među kojima svojom učestalošću prednjače bolesti kardiovaskularnog sistema.

show abstract

TNF-α Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis

Cited by 72 publications

References 32 publications

Efficacy and Safety of Rituximab in Elderly Patients With Rheumatoid Arthritis Enrolled in a French Society of Rheumatology Registry

Efficacy and Safety of Rituximab in Elderly Patients With Rheumatoid Arthritis Enrolled in a French Society of Rheumatology Registry

Targeted Therapy and Infections in Rheumatic Diseases

Komorbiditeti kod oboljelih od reumatoidnog artritisa

Contact Info

Product

Resources

About